← Back
$APLS All transactions

Apellis Pharmaceuticals, Inc.

▼ SELL

$ Value

$523K

Shares

20,000

Price

$26

Filed

Sep 12

Insider

Name

Watson David O.

Title

General Counsel

CIK

0001657719

Roles

Officer

Transaction Details

Transaction Date

2025-09-10

Code

S

Table

Non-Derivative

Ownership

Indirect

Equity Swap

No

Shares After

50,136

Footnotes

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.15 to $26.20, inclusive. The reporting person hereby undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. | The securities are held by The David O. Watson Irrevocable Trust of 2023. William Zorn is the trustee of The David O. Watson Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The David O. Watson Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein. | This represents a custodial account held by the reporting person for the sole benefit of his minor children.

Filing Info

Accession No.

0001193125-25-202168

Form Type

4

Issuer CIK

0001492422

Watson David O.'s History

Date Ticker Type Value
2026-01-28 APLS A $0
2026-01-22 APLS $170K
2026-01-20 APLS $49K
2026-01-13 APLS $128K
2026-01-07 APLS M $13K
2026-01-07 APLS M $0
2025-12-16 APLS $122K
2025-11-17 APLS $100K
2025-10-16 APLS $126K
2025-09-16 APLS $122K

Other Insiders at APLS (90d)

Insider Bought Sold Last
Dolsten Mikael 2026-02-27
Watson David O.
General Counsel
2026-01-28
Deschatelets Pascal
Chief Scientific Officer
2026-01-28
Francois Cedric
Chief Executive Officer
2026-03-11
Sullivan Timothy Eugene
Chief Financial Officer
2026-04-17
O'Brien Stephanie Monaghan 2026-04-06
Nicholson Nur
Chief Technical Officer
2026-01-28
Chopas James George
VP/Chief Accounting Officer
2026-01-28
DeLong Mark Jeffrey
Chief Business & Strat Officer
$8K 2026-02-11
Boucher Kelley
Chief People Officer
2026-01-28
MELTZER LESLIE
Chief Research and Development
2026-01-28